Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11411106 | 1.00 | TRPV1 (0.75) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL6445172 | 1.00 | TRPV1 (0.75) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL11411110 | 1.00 | TRPV1 (0.75) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL6445166 | 1.00 | TRPV1 (0.75) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL584936 | 0.99 | TRPV1 (0.77) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL584937 | 0.99 | TRPV1 (0.77) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL5312466 | 0.99 | TRPV1 (0.77) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL5605086 | 0.99 | TRPV1 (0.77) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL8625199 | 0.95 | TRPV1 (0.72) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL8625206 | 0.95 | TRPV1 (0.72) | TRPV1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176311-A1 | Composition and method for treating cancer | MO HUANBIAO (US) | 2004-09-09 | — | — | US | claimed |
| US-6699850-B2 | ORAL FORMULATION OF A COMBINATION OF NITROGEN-CONTAINING BISPHOSPHONATE OR ITS SALT AND AN ISOPRENOID COMPOUND FOR INHIBITING BONE RESOPRTION IN A MAMMAL WHILE COUNTERACTING THE OCCURRENCE OF ADVERSE GASTROINTESTINAL EFFECT | MERCK & CO., INC. | 2004-03-02 | — | — | US | claimed |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | MERCK & CO., INC. | 2002-06-27 | — | — | US | claimed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | claimed |
| EP-1061907-A1 | MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-12-27 | — | — | EP | claimed |
| WO-1999045912-A1 | MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-09-16 | — | — | WO | claimed |
| US-4214909-A | SESQUITERPENE ALCOHOLS AND CARBOXYLIC ACID ESTERS THEREOF | KURARAY CO., LTD. (JP) | 1980-07-29 | — | — | US | claimed |
| CN-108250055-B | Preparation method of pyruvylgeranyl pyrophosphate intermediate | 重庆医药工业研究院有限责任公司 | 2022-08-05 | — | — | CN | disclosed |
| US-9199900-B2 | Method for converting farnesol to nerolidol in the presence of alpha-bisabolol | SYMRISE AG (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20130289317-A1 | Method for Converting Farnesol to Nerolidol in the Presence of Alpha-Bisabolol | SYMRISE AG (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20100222606-A1 | METHOD FOR PRODUCING BISABOLOL WHICH IS FARNESOL FREE OR IS LOW IN FARNESOL | BASF SE (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7074825-B2 | Composition and method for treating cancer | MO HUANBIAO | 2006-07-11 | — | — | US | disclosed |
| US-6911318-B2 | Bacterial transglycosylases: assays for monitoring the activity using Lipid II substrate analogs and methods for discovering new antibiotics | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2005-06-28 | — | — | US | disclosed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | disclosed |
| EP-1061907-A1 | MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1061907-A1 | MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000052035-A1 | BACTERIAL TRANSGLYCOSYLASES: ASSAYS FOR MONITORING THE ACTIVITY USING LIPID II SUBSTRATE ANALOGS AND METHODS FOR DISCOVERING NEW ANTIBIOTICS | PRINCETON UNIVERSITY (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999045912-A1 | MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999045912-A1 | MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-09-16 | — | — | WO | disclosed |
| US-5466718-A | Inhibiting melanin formation | TAKASAGO INSTITUTE FOR INTERDISCIPLINARY (US) | 1995-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289317-A1 | Method for Converting Farnesol to Nerolidol in the Presence of Alpha-Bisabolol | FNTB, FNTA, FHIT | TRPV1 2002/4885ALDH1A1 938/4885ALOX15 2071/4885 |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | SOST, PTEN, ALPI | TRPV1 1672/4885ALDH1A1 4552/4885ALOX15 441/4885 |
| US-20100222606-A1 | METHOD FOR PRODUCING BISABOLOL WHICH IS FARNESOL FREE OR IS LOW IN FARNESOL | FHIT, FDPS, FNTA | TRPV1 592/4885ALDH1A1 856/4885ALOX15 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.